Diabetic macular edema (DME) is an eye condition that can lead to vision loss in people with diabetes. It occurs as a result of diabetic retinopathy — damaged blood vessels in the eyes due to elevated ...

Although corticosteroids were found to immediately improve best-corrected visual acuity and central macular thickness, anti–vascular endothelial growth factor (anti-VEGF) therapies had significant ...

Susvimo is an FDA-approved eye implant for diabetic macular edema that may reduce monthly injections to just two treatments a ...

The optic cup and macula of a 24-year-old female. Image is released to Wikimedia commons with patient consent. Imaged with a non-mydriatic fundus camera at Pacific University College of Optometry.

Diabetic eye disease is a leading cause of vision loss in individuals aged 20 to 74,(3) and diabetic macular edema (DME), left untreated, is the leading cause of blindness in diabetic patients. The ...

Please provide your email address to receive an email when new articles are posted on . Lamivudine improved visual acuity in patients with center-involved diabetic macular edema. Researchers said the ...

A recent study published in the journal Nature Medicine showed that targeting senescent cells in the retina can be a lasting disease-modifying treatment for diabetic macular edema (DME). The retina is ...

Patients with diabetic macular edema could be treated with brolucizumab with as much effectiveness as aflibercept. There were no clinically meaningful differences in visual outcomes when patients with ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. UBX1325 met safety and efficacy endpoints at 24 weeks in ...

Fluocinolone implants can slow diabetic retinopathy and delay proliferation in patients with diabetic macular edema, researchers say. Compared with antivascular endothelial growth factor (anti-VEGF) ...

The trials are evaluating DURAVYU (vorolanib intravitreal insert) for the treatment of diabetic macular edema (DME).

LONDON--(BUSINESS WIRE)--The global diabetic macular edema treatment market 2018-2022 is expected to post a CAGR of more than 1% during the forecast period, according to the latest market research ...